| Release Date: January 2008 | Valid Through: December 31, 2008 |
Credits Available: Physicians - 1.0 AMA PRA Category 1 Credit(s)TM
| Fee: There is no fee for this activity. |
| Target Audience: This CME activity is designed for oncology professionals who treat patients with metastatic breast cancer. |
This CME activity is based on the following:
Expert Interview SABCS 2007: Highlights and Clinical Implications for Metastatic Breast Cancer
An interview with Dr. Lee Schwartzberg, available in streaming audio, downloadable podcast, and printable transcription format.
- Streaming Audio
- Transcript
- Post Test
Listen to the audio version below: Get the Flash Player to see this player.
| Click here to view a transcript of this activity, including the references. | Click here for the post test. |
Lee Schwartzberg, MD
Dr. Lee Schwartzberg is a senior partner at The West Clinic in Memphis, Tennessee. He did a residency in Internal Medicine at Cornell University and fellowship training in Hematology and Oncology at Memorial Sloan-Kettering Cancer Center where he was chief resident in Medicine. He is a Clinical Professor of Medicine at The University of Tennessee College of Medicine. He serves as the Medical Director of the Baptist Cancer Institute-Stem Cell Transplant Program and the Cancer Assessment Risk Evaluation and Surveillance (CARES) Genetics Program. Dr. Schwartzberg has authored over fifty research papers and serves as the Director of Research for The West Clinic.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Consider the clinical impact of emerging therapies on survival and quality of life for metastatic breast cancer.
- Define the optimal combinations, duration, and schedules of therapy directed against HER2.
- Evaluate new data with regard to the outcomes achieved with novel anti-VEGF and anti-angiogenic treatment strategies in patients with metastatic breast cancer.
- Understand the potential differences and benefits of newer targeted therapies used alone or in combination with regard to their impact on survival, safety, and quality of life.
- Understand novel chemotherapeutic agents emerging in the management of metastatic breast cancer.
Supporters
This activity is supported by an educational grant from Bristol-Myers Squibb Company, Wyeth Pharmaceuticals, and an educational donation provided by Amgen.
